Form 4: VolitionRx Executive Gael Forterre Reports Stock Transactions

Gael Forterre, Chief Commercial Officer of VolitionRx, reports acquisition of shares through RSU vesting and cancellation of unvested RSUs.

Summary

• On August 15, 2024, Gael Forterre, the Chief Commercial Officer of VolitionRx, reported transactions involving the company's stock.
• Mr. Forterre acquired 15,250 shares of common stock through the vesting of restricted stock units (RSUs) at a price of $0.00.
• These RSUs were part of an award of 61,000 RSUs granted on September 28, 2023, under the company's 2015 Stock Incentive Plan.
• The vesting of these RSUs was contingent upon achieving certain corporate performance goals by December 31, 2023, and June 30, 2024, as well as a 3-year time-based vesting schedule.
• Certain performance goals were met, leading to the vesting of the 15,250 RSUs.
• The RSUs are subject to a 3-year time-based vesting schedule, vesting in three installments of 5,083 units, 5,083 units, and 5,084 units on each of Sept 28, 2024, 2025 and 2026, respectively.
• Additionally, 19,825 RSUs did not vest and were cancelled on August 15, 2024.
• Following these transactions, Mr. Forterre directly owns 152,370 shares of VolitionRx common stock.
• He also indirectly owns 5,000 shares through his spouse and 32,500 shares through Armori Capital Management, LLC, where he is the managing director and sole shareholder.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. The vesting of RSUs suggests some performance goals were met, but the cancellation of other RSUs indicates some goals were missed. Overall, it's a mixed bag with no major cause for concern or celebration.

Positives

• The vesting of RSUs indicates that certain corporate performance goals were achieved, which is a positive sign for the company.

Negatives

• The cancellation of 19,825 RSUs suggests that some performance goals were not met, which could be a concern.

Risks

• The vesting of RSUs is tied to both performance and time-based criteria, creating uncertainty regarding future vesting events.
• Dependence on performance goals for equity compensation could lead to pressure to achieve short-term targets at the expense of long-term sustainability.

Future Outlook

The reporting person will receive shares of common stock equal to the number of RSUs that have vested upon settlement, and the remaining vested RSUs are subject to a 3-year time-based vesting schedule.

Industry Context

This filing is a routine disclosure related to executive compensation and stock ownership, common in publicly traded companies. It provides transparency into the alignment of management's interests with those of shareholders.

Comparison to Industry Standards

• RSU grants are a common form of executive compensation in the biotechnology and pharmaceutical industries, often used to incentivize performance and retain key personnel.
• Vesting schedules tied to both performance and time are also standard practice, aligning executive rewards with company milestones and long-term growth.
• Companies like Exact Sciences and Guardant Health also utilize similar equity compensation plans for their executives.

Stakeholder Impact

• Shareholders may view the vesting of RSUs as a positive sign, indicating that management is incentivized to achieve company goals.
• Employees may be affected by the achievement or failure to achieve performance goals, which can impact morale and future compensation.

Next Steps

• The reporting person will continue to vest in the remaining RSUs according to the time-based vesting schedule.
• Future Form 4 filings will likely be required as additional RSUs vest or other transactions occur.

Key Dates